EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Taito Fukushima iD, Manabu Morimoto, Satoshi Kobayashi iD, Makoto Ueno, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Yoshitaka Arase, Tatehiro Kagawa und 5 weitere

The Oncologist · 05.07.2023 · 28 (7) · e526-e533

DOI: 10.1093/oncolo/oyad090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 06.04.2023. Verfasst von Taito Fukushima und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) are effective for advanced hepatocellular carcinoma (HCC). However, there are few reports on the correlation between the clinical efficacy of ICIs and the development of immune-related adverse events (irAEs) in patients with HCC. The aim of this study was to investigate the association between irAE development and survival in patients with HCC treated with atezolizumab plus bevacizumab. Patients and Methods We enrolled 150 patients with advanced HCC treated with atezolizumab plus bevacizumab between October 2020 and October 2021 at 5 territorial institutions. We compared the efficacy of atezolizumab plus bevacizumab between patients who experienced irAEs (irAE group) and those who did not (non-irAE group).

Results

Thirty-two patients (21.3%) developed irAEs of any grade. Grade 3/4 irAEs were observed in 9 patients (6.0%). The median progression-free survivals (PFS) in the irAE and non-irAE groups were 273 and 189 days, respectively (P = .055). The median overall survivals (OS) in the irAE and non-irAE groups were not reached and 458 days, respectively (P = .036). Grade 1/2 irAEs significantly prolonged PFS (P = .014) and OS (P = .003). Grade 1/2 irAEs were significantly associated with PFS (hazard ratio [HR], 0.339; 95% confidence interval [CI], 0.166-0.691; P = .003) and OS (HR, 0.086; 95% CI, 0.012-0.641; P = .017) on multivariate analysis.

Conclusion

The development of irAEs was associated with increased survival in a real-world population of patients with advanced HCC treated with atezolizumab plus bevacizumab. Grade 1/2 irAEs were strongly correlated with PFS and OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsDrug-Related Side Effects and Adverse ReactionsHumansNivolumabBevacizumabRetrospective StudiesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Atezolizumab plus bevacizumabhepatocellular carcinomaimmune-related adverse eventsimmunotherapylandmark analysis

Substanzen

NivolumabBevacizumabatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Gastroenterology Division, Hadano Red Cross Hospital, Hadano, Japan.

ORCID-Profile: Taito Fukushima, Satoshi Kobayashi

Zitieren

APA

Fukushima, T., Morimoto, M., Kobayashi, S., Ueno, M., Uojima, H., Hidaka, H., Kusano, C., Chuma, M., Numata, K., Tsuruya, K., Arase, Y., Kagawa, T., Hattori, N., Ikeda, H., Watanabe, T., Tanaka, K., & Maeda, S. (2023). Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. The Oncologist, 28(7), e526-e533. https://doi.org/10.1093/oncolo/oyad090

Vancouver

Fukushima T, Morimoto M, Kobayashi S, Ueno M, Uojima H, Hidaka H, et al. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. The Oncologist. 2023;28(7):e526-e533. doi:10.1093/oncolo/oyad090

BibTeX
@article{Fukushima2023,
  author = {Fukushima, Taito and Morimoto, Manabu and Kobayashi, Satoshi and Ueno, Makoto and Uojima, Haruki and Hidaka, Hisashi and Kusano, Chika and Chuma, Makoto and Numata, Kazushi and Tsuruya, Kota and Arase, Yoshitaka and Kagawa, Tatehiro and Hattori, Nobuhiro and Ikeda, Hiroki and Watanabe, Tsunamasa and Tanaka, Katsuaki and Maeda, Shin},
  title = {Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {7},
  pages = {e526--e533},
  doi = {10.1093/oncolo/oyad090}
}
Kostenlos starten →